Abstract:Glioblastoma (GBM) is the most common type of malignant tumor of the central nervous system. The prognosis of patients with GBM is very poor, with a survival time of ~15 months. GBM is highly heterogeneous and highly aggressive. Surgical removal of intracranial tumors does provide a good advantage for patients as there is a high rate of recurrence. The understanding of this type of cancer needs to be strengthened, and the aim of the present study was to identify gene signatures present in GBM and uncover their potential mechanisms. The gene expression profiles of GSE15824 and GSE51062 were downloaded from the Gene Expression Omnibus database. Normalization of the data from primary GBM samples and normal samples in the two databases was conducted using R software. Then, joint analysis of the data was performed. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed, and the protein‑protein interaction (PPI) network of the differentially expressed genes (DEGs) was constructed using Cytoscape software. Identification of prognostic biomarkers was conducted using UALCAN. In total, 9,341 DEGs were identified in the GBM samples, including 9,175 upregulated genes and 166 downregulated genes. The top 1,000 upregulated DEGs and all of the downregulated DEGs were selected for GO, KEGG and prognostic biomarker analyses. The GO results showed that the upregulated DEGs were significantly enriched in biological processes (BP), including immune response, cell division and cell proliferation, and the downregulated DEGs were also significantly enriched in BP, including cell growth, intracellular signal transduction and signal transduction by protein phosphorylation. KEGG pathway analysis showed that the upregulated DEGs were enriched in circadian entrainment, cytokine‑cytokine receptor interaction and maturity onset diabetes of the young, while the downregulated DEGs were enriched in the TGF‑β signaling pathway, MAPK signaling pathway and pathways in cancer. All of the downregulated genes and the top 1,000 upregulated genes were selected to establish the PPI network, and the sub‑networks revealed that these genes were involved in significant pathways, including olfactory transduction, neuroactive ligand‑receptor interaction and viral carcinogenesis. In total, seven genes were identified as good prognostic biomarkers. In conclusion, the identified DEGs and hub genes contribute to the understanding of the molecular mechanisms underlying the development of GBM and they may be used as diagnostic and prognostic biomarkers and molecular targets for the treatment of patients with GBM in the future.

Potential Molecular Mechanism of TNF Superfamily-Related Genes in Glioblastoma Multiforme Based on Transcriptome and Epigenome

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Comprehensive Analysis of the Brain-Expressed X-Link Protein Family in Glioblastoma Multiforme

Modulation of Tumor Immune Microenvironment and Prognostic Value of Ferroptosis-Related Genes, and Candidate Target Drugs in Glioblastoma Multiforme

A Novel Immune-Related Prognostic Biomarker and Target Associated With Malignant Progression of Glioma

Comprehensive analysis of a TNF family based-signature in diffuse gliomas with regard to prognosis and immune significance

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Multi-omics approaches establishing histone modification based prognostic model in glioma patients and further verification of the carcinogenesis mechanism

Novel tumor necrosis factor-related long non-coding RNAs signature for risk stratification and prognosis in glioblastoma

Whole Transcriptome and Proteome Analyses Identify Potential Targets and Mechanisms Underlying Tumor Treating Fields Against Glioblastoma

Molecular and Clinicopathological Characterization of a Prognostic Immune Gene Signature Associated With MGMT Methylation in Glioblastoma

Multicellular biomarkers of drug resistance as promising targets for glioma precision medicine and predictors of patient survival

Identification of Differentially Expressed Genes in Different Glioblastoma Regions and Their Association with Cancer Stem Cell Development and Temozolomide Response

Systematic analysis of the long noncoding RNA (lncRNA)-miRNA-mRNA competing endogenous RNA network to identify prognostic biomarkers and the potential regulatory axis in glioblastoma multiforme

Identifying Predictive Gene Expression and Signature Related to Temozolomide Sensitivity of Glioblastomas

Integrated Transcriptome Analyses and Experimental Verifications of Mesenchymal-Associated TNFRSF1A As a Diagnostic and Prognostic Biomarker in Gliomas.

Identification of Hub Genes and Regulatory Factors of Glioblastoma Multiforme Subgroups by RNA-seq Data Analysis

Novel Biomarker Genes for Prognosis of Survival and Treatment of Glioma

Development of an Immune-Related Prognostic Index Associated with Glioblastoma

Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma

A Novel Prognostic Signature of Transcription Factors for the Prediction in Patients with GBM.